New Daily Persistent Headache (NDPH)
0
Pipeline Programs
1
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
2027
TheranicaNerivio
TheranicaNerivio
Clinical Trials (2)
Total enrollment: 40 patients across 2 trials
An Open Label Study Assessing REN Treatment in Headache Management in Temporomandibular Disorders
Start: May 2026Est. completion: Jan 202740 patients
N/ARecruiting
Nerivio Device for Treatment of New Daily Headache Persistence (NDHP)
Start: Feb 2022Est. completion: Sep 20230
N/AWithdrawn
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 40 patients
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.